Artificial Organs for Heart Research
The artificial production of heart muscle tissue offers a promising approach for the development of new drugs against cardiovascular diseases, which are the leading cause of death worldwide. The project “AI-based Optimization of the Production of Cardiac Bodies” aims to make the production process of Cardiac Bodies – a precursor of complete heart tissue – more efficient and robust. This will enable the production of functional heart tissue of high quality, which is essential for research as well as the development of innovative therapies.
AI and Biotechnology
Artificial intelligence will be applied in two specific areas of the project. On the one hand, the complex biotechnological production process itself will be optimized through machine learning. In addition, the research on Cardiac Bodies generates large volumes of data, which are managed using the LinkAhead data management system. To simplify data analysis, the search language of LinkAhead will be significantly enhanced by the use of Large Language Models (LLMs). This will particularly improve complex search queries.
The project is supported by NBank within the framework of the Lower Saxony Innovation Funding Program for Research and Development in Companies, co-financed by the European Union, and runs from May 1, 2025 to April 30, 2026.
Further information about the two Göttingen-based companies myotwin GmbH and IndiScale GmbH
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary myoScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
